Boston Molecules established proprietary recombinant protein technology for mammalian expression with features:
- HEK293 mammalian expression platform integrated with chaperone-assisted
protein expression technology
- Proper folding, disulfide bonding, and N-linked glycosylation.
- Low endotoxin <0.10 EU per 1 μg of the protein
- Average protein activity ~ 5-10 fold higher than R&D system and PeproTech.